Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV MediciNova, Inc. daily Stock Chart
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own22.50% Shs Outstand34.40M Perf Week1.22%
Market Cap200.21M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float29.89M Perf Month-0.51%
Income-10.90M PEG- EPS next Q-0.09 Inst Own27.60% Short Float7.54% Perf Quarter-3.32%
Sales- P/S- EPS this Y1.00% Inst Trans-0.02% Short Ratio53.11 Perf Half Y-19.50%
Book/sh1.00 P/B5.82 EPS next Y- ROA-26.10% Target Price11.00 Perf Year-17.45%
Cash/sh0.70 P/C8.31 EPS next 5Y20.00% ROE-29.60% 52W Range4.85 - 8.00 Perf YTD-3.48%
Dividend- P/FCF- EPS past 5Y22.70% ROI- 52W High-27.25% Beta0.59
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low20.00% ATR0.32
Employees10 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)51.57 Volatility6.39% 4.62%
OptionableYes Debt/Eq0.00 EPS Q/Q54.00% Profit Margin- Rel Volume1.29 Prev Close6.02
ShortableYes LT Debt/Eq0.00 EarningsApr 26 Payout- Avg Volume42.45K Price5.82
Recom1.00 SMA203.20% SMA50-1.14% SMA200-10.31% Volume54,750 Change-3.32%
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Apr-25-17 07:00PM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston GlobeNewswire
Apr-09-17 07:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois GlobeNewswire
Feb-27-17 06:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland GlobeNewswire +5.74%
12:00PM  MNOV: MN-166 Making Progress in Numerous Indications Zacks Small Cap Research
Feb-18-17 01:04PM  MEDICINOVA INC Financials
Feb-15-17 08:42AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-14-17 06:26PM  MEDICINOVA INC Files SEC form 10-K, Annual Report
Feb-07-17 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston GlobeNewswire
Feb-06-17 06:00PM  MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research GlobeNewswire
Feb-01-17 06:00PM  MediciNova to Attend Mizuho Healthcare Conference in New York GlobeNewswire
Jan-23-17 06:00PM  MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Dec-22-16 11:30AM  MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion Zacks Small Cap Research
Dec-20-16 06:00PM  MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire -6.52%
Dec-19-16 06:00AM  MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis GlobeNewswire
Dec-15-16 10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 Capital Cube
10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
Dec-14-16 06:00AM  MediciNova Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-09-16 06:00AM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Nov-14-16 06:00AM  MediciNova to Present at the Piper Jaffray Healthcare Conference in New York GlobeNewswire +6.73%
Nov-10-16 05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:00AM  MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
Nov-07-16 06:00PM  MediciNova to Attend Global Mizuho Investor Conference in New York GlobeNewswire
Oct-30-16 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Oct-27-16 11:00AM  MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS Zacks Small Cap Research
Oct-26-16 10:20AM  MediciNova reports 3Q loss
06:05AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-25-16 05:20PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-11-16 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
02:35PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016 Capital Cube
02:35PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Sep-25-16 07:00PM  Options on MediciNova Common Stock Listed on CBOE GlobeNewswire
Sep-16-16 05:17PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Jul-29-16 12:00PM  MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
Jul-27-16 06:12AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Jul-26-16 05:18PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Jul-24-16 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis GlobeNewswire
Jul-13-16 06:30AM  MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-29-16 07:00PM  MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana GlobeNewswire
Jun-26-16 07:00PM  MediciNova Added to Russell 3000® Index and Russell Global Index GlobeNewswire
Jun-13-16 06:08AM  MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.18%
Jun-06-16 02:27PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-25-16 07:00PM  MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana GlobeNewswire
Apr-29-16 04:25PM  MNOV: Positive Trends Seen in Preliminary Data Presented on MN-166 in ALS
Apr-28-16 06:21AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Apr-27-16 04:55PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Apr-20-16 06:00AM  MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire -6.56%
Apr-04-16 08:02AM  MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street Accesswire +13.92%
Mar-31-16 07:55AM  MediciNova Gains 6% Following Positive Mention In Medical Journal
06:32AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic
Mar-30-16 07:00PM  MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire +11.11%
Mar-27-16 07:20PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China GlobeNewswire
Mar-23-16 07:27PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia GlobeNewswire
Mar-22-16 06:29AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis at noodls
06:09AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis GlobeNewswire
Mar-14-16 01:57PM  LifeSci Capital Initiates Coverage of MediciNova Accesswire
09:00AM  Biotech Trade Report Accesswire
Mar-09-16 11:00AM  MNOV: Multiple Catalysts Ahead in 2016
Mar-07-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire
Mar-06-16 06:00PM  MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas GlobeNewswire
Mar-01-16 08:46AM  MediciNova, Inc. (NASDAQ: MNOV) Ongoing Clinical Trial of MN-166 Accesswire
Feb-26-16 09:15AM  3 Stocks That Should be in Your Portfolio Today Accesswire -10.59%
06:41AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-25-16 05:19PM  MEDICINOVA INC Files SEC form 10-K, Annual Report +10.69%
03:04PM  3 Biotech Stocks to Consider Buying Right Now Accesswire
10:15AM  4 Stocks That Are Starting To Attract Major Attention Today Accesswire
Feb-22-16 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire +5.98%
Feb-11-16 06:00PM  MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Feb-07-16 06:00PM  MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Jan-27-16 06:18PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis at noodls
06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis GlobeNewswire
Jan-18-16 06:00PM  FDA Grants Rare Pediatric Disease Designation to MediciNovas MN-166 (ibudilast) for the Treatment of Krabbe Disease GlobeNewswire
Jan-13-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe GlobeNewswire
Dec-16-15 02:30PM  MNOV: Positive Interim Safety and Clinical Data Presented at 26th International Symposium on ALS/MND
06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-14-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China GlobeNewswire
Dec-13-15 06:00PM  MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Dec-09-15 05:30PM  MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting GlobeNewswire
Dec-06-15 06:00PM  MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California GlobeNewswire
Dec-02-15 07:45AM  Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova Accesswire
Nov-27-15 08:06AM  Is MediciNova, Inc. (MNOV) A Good Stock To Buy? at Insider Monkey
Nov-23-15 09:56AM  Is Timmins Gold Corp (TGD) A Good Stock To Buy? at Insider Monkey
Nov-19-15 06:00AM  MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia GlobeNewswire
Nov-10-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan GlobeNewswire
Nov-09-15 06:00PM  FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital) GlobeNewswire
Nov-04-15 06:00AM  MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida GlobeNewswire
Nov-02-15 03:00PM  MNOV: Presentation on ALS Phase 2 Study in December
Oct-30-15 06:14AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-29-15 05:19PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-13-15 07:00PM  MediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Oct-09-15 06:00AM  MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF GlobeNewswire
Sep-25-15 05:11PM  15 Stocks Moving In Friday's After-Hours Trading
05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-24-15 06:00AM  MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference GlobeNewswire
Sep-10-15 06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-08-15 11:35AM  MNOV: Phase 2 ALS Trial Expanded
Sep-02-15 07:00PM  MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast) GlobeNewswire
Sep-01-15 06:06AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Aug-25-15 06:04AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kobayashi YutakaDirectorSep 15Buy6.4411,80075,99281,800Sep 15 02:10 PM
Kobayashi YutakaDirectorSep 09Buy6.6710,00066,70070,000Sep 09 06:29 PM
OBrien GeoffreyVice PresidentJul 05Option Exercise4.803,30015,8408,300Jul 07 06:30 PM
OBrien GeoffreyVice PresidentJul 05Sale8.003,30026,4005,000Jul 07 06:30 PM